Stockreport

Momenta Pharmaceuticals Announces Oral Presentation of New Data for M281 at the Society for Maternal-Fetal Medicine 2019 Annual Meeting

MOMENTA PHARMACEUTICALS  (MNTA) 
Last momenta pharmaceuticals earnings: 2/26 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.momentapharma.com/investor-relations
PDF Study highlights ability of M281 to inhibit transfer of immunoglobulin G from maternal to fetal circulation in ex vivo placental perfusion modelM281 currently being eval [Read more]